##  [FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis](/us-en/news/media-releases/fda-accepts-biologics-license-application-amg-334-erenumab-important-regulatory-milestone-novartis-0 "FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis") 

  Jul 20, 2017